In a follow-up investigation of responses to WD-PR (Pereira et al., 2022), intracerebroventricular (ICV) injection of losartan (an AT1R antagonist) was found to have no effect on orofacial reactions to IO of 0.3 M NaCl in E2-treated SHRs (Figure 1, right). This evidence concerns the gene AGTR1 and Wilson disease.